Canada - English - Health Canada

mylan pharmaceuticals ulc - irbesartan - tablet - 150mg - irbesartan 150mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

mylan pharmaceuticals ulc - irbesartan; hydrochlorothiazide - tablet - 150mg; 12.5mg - irbesartan 150mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - irbesartan; hydrochlorothiazide - tablet - 300mg ; 12.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - hydrochlorothiazide; irbesartan - tablet - 25mg ; 300mg

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n) - irbesartan 150 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - irbesartan - tablet - 75mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - irbesartan - tablet - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - irbesartan - tablet - 300mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; povidone; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 3350; iron oxide black - abisart hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - hydrochlorothiazide; irbesartan - tablet - 12.5mg ; 150mg